From metabolic drug to mood modulator A new paper in Cell Host & Microbe has just delivered one of the most compelling mechanistic stories yet for how the endocannabinoid system (ECS) links metabolic drugs, the gut microbiome, and mood regulation. The study shows that the antidepressant effects of the GLP‑1…
Tag: Endocannabinoid system
ECS Literacy in Medicine: Why It Makes Better Doctors
What happens to clinical reasoning when a physician understands the endocannabinoid system? Seven conditions, two kinds of doctors, and the reasoning gap that a better curriculum could close.
How Poor Diet and Insulin Spikes Disrupt the Endocannabinoid System and Drive Fatty Liver
Scientists have identified a new mechanism linking everyday diet to endocannabinoid system (ECS) dysfunction: normal post‑meal insulin spikes can increase CB1 receptors in the liver by about 50% by slowing their lysosomal recycling. Together with an omega‑6‑heavy fat intake, this amplifies diet‑driven steatosis and helps explain how common foods drive fatty liver disease.
Low plasma linoleic acid is a marker of high FADS activity – not a license to drink seed oil
A new UK Biobank paper on omega‑6 and adiposity just landed, and if you only read the abstract, you’d think the story was simple: higher linoleic acid (LA) in plasma is “protective” against obesity and therefore we should be recommending more LA‑rich oils to everyone. Look one level deeper, and…
Why an Omega-3 Trial for Anxiety Accidentally Proved Something Far More Interesting About Your Endocannabinoid System
A new randomised, double-blind, placebo-controlled trial published in the Journal of Affective Disorders set out to test whether omega-3 supplementation improves stress, anxiety, depression, sleep quality, and memory in people with severe psychological distress (Azhar et al., 2025). The trial was conducted on a Saudi population, was reasonably well-designed, and produced striking…
Your ECS Under Load: Regular Cannabis, Exercise, and a Blunted Runner’s High
Your ECS under load, not at rest Most cannabis conversations live in the acute space: “How does it feel when I’m high?” or in vague long‑term boxes like “motivation” or “psychosis risk.” Almost nobody asks the more mechanistic question that actually matters for resilience: What does your endocannabinoid system do…
The Medical Cannabis Paradox: How Tolerance Threatens Long-Term Therapeutic Success
A follow-up to “CB1 Availability as a Non-Invasive Biomarker: Bridging Endocannabinoid System Dysfunction and Therapeutic Monitoring“ The Emerging Evidence: Tolerance is Real and Quantifiable A recent study published in Frontiers in Pharmacology (2025) provided the first systematic measurement of how tolerance accumulates during medical cannabis treatment (Stith et al., 2025). Using real-world…
The New US Dietary Guidelines: Eat to Support Your ECS
This article explains how the endocannabinoid system is shaped by diet, especially omega‑6 and omega‑3 fats. The 2025–2030 US Dietary Guidelines process is quietly doing something profound. On the surface, it might look like another technical update about fat intake, unsaturated oils, and seafood recommendations. But underneath that familiar language sits…
A Future Where CB1 Is Visible: CB1 Availability Biomarkers
Medical cannabis is still prescribed around an invisible axis: CB1 receptor capacity. This vision explores a future where CB1 availability is visible as a simple percentage on your phone, guiding dosing, tolerance, safety, and a new era of ECS medicine.
2025 in ECS Research: The Year the Substrate-Driven ECS Model Came of Age
Endocannabinoid system substrate—specifically membrane fatty acid composition—is the primary determinant of CB1 receptor function, not genetics or receptor density. For years, I’ve been making the case that endocannabinoid system function is not primarily about receptor density or genetic variants, it’s about substrate availability. The composition of fatty acids in cell…
